Genmab's Cancer Survival Gain & Lilly's Retatrutide Dose Trade-Off

This is the October 28 edition of The Pharma Closeout, released October 29.Genmab's investigational petosemtamab combination improves survival against pembrolizumab alone in a first-line head-and-neck cancer trial, while Lilly's retatrutide raises a dose-choice question after greater weight loss and more adverse-event discontinuations than Ozempic (semaglutide) 2 mg in type 2 diabetes. Geron stops imetelstat's myelofibrosis trial; AbbVie files etentamig for multiple myeloma using previously reported CERVINO results; and Replimune reports early launch activity for TUDRIQEV (vusolimogene oderparepvec-wtpg) in melanoma. FDA's draft individualized gene-editing framework, CMS's planned gene-therapy access expansion and HHS's proposed conditional peptide-compounding policy remain distinct developments. GSK's sales mix shifts toward specialty medicines, and FDA staff questions set up the October 30 advisory committee on Sydnexis's atropine for pediatric myopia.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.